UroAlert - GU Oncology Weekly

October 16, 2025

Videos

Peer-to-Peer Clinical Conversations

Lutetium Lu 177 Timing Study: Early vs. Late Post-Chemo PSA Response - Eman Ahmed & Jack Andrews

Jack Andrews

Zachary Klaassen discusses lutetium-177 PSMA radioligand therapy timing with Jack Andrews and Eman Ahmed.

CREST Trial First Interim Analysis: Extending Event-Free Survival and Advancing Care in High-Risk NMIBC - Neal Shore

Neal Shore

Ashish Kamat speaks with Neal Shore about the CREST trial results in high-risk non-muscle invasive bladder cancer.

Beyond the Abstracts

MUlticentre REtrospective Comparison of Definitive EBRT with or Without HDR BRAchytherapy Boost in Patients with Locally-Advanced Prostate Cancer and Regional Lymph NOde Metastases (MUREBRANO) - a Propensity Score Matched Analysis - Beyond the Abstract

The Impact of Prophylactic Incisional Negative Pressure Wound Therapy on Surgical Site Infection Following Open Radical Cystectomy - Beyond the Abstract

Conference Coverage

SCU 2025: Use of Artificial Intelligence in Screening, Diagnosis, and Treatment of Prostate Cancer

SCU 2025: Tumor Markers in Prostate Cancer: 2025 Update

BCANTT 2025: Balancing Innovation and Affordability: Collaborative Pathways in Bladder Cancer Care

BCANTT 2025: Exploring Therapeutic Vulnerabilities for Drug Development in Bladder Cancer Using down Syndrome as a Novel Model

BCANTT 2025: Overcoming Immune Suppressive Myeloid Cell Barriers in Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Photocure and Intelligent Scopes Corporation Partner on Development of AI for Blue Light Cystoscopy

TAR-200 for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Expert Commentary

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

Comparison of 90-day morbidity and mortality between ileal conduit and orthotopic neobladder following radical cystectomy in a large multi-institutional database: The Canadian CBCIS experience.

Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder Cancer.

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Urinary Biomarkers for Immunotherapy Response in Urothelial Carcinoma: Current Status and Future Outlook.

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

Evaluating Surrogates for Overall Survival in the Adjuvant Treatment of Bladder Cancer with Chemotherapy - Beyond the Abstract

Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.

The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion - Beyond the Abstract

The Impact of Prophylactic Incisional Negative Pressure Wound Therapy on Surgical Site Infection Following Open Radical Cystectomy - Beyond the Abstract

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries.

Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer.

Penile & Urethral Cancers

Inguinal and pelvic lymph node dissection in penile cancer: indications, techniques, and trends.

Psycho-oncological and psychosexual consequences of penile cancer: what can we offer our patients?.

Renal Cancer

Lipid Metabolism of Clear Cell Renal Cell Carcinoma Predicts Survival and Affects Intratumoral CD8 T Cells - Beyond the Abstract

A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma.

Case Report: En bloc resection of inferior vena cava and renal cell carcinoma with level IV tumor thrombus associated with tumor thrombus embolization to the pulmonary arteries: presence of blood vessels inside the tumor thrombus.

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.

HIF-2-dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear Cell Renal Cell Carcinoma.

Outcomes of Cystic Versus Solid Renal Masses After Surgery: A Prospective Single-centre Comparative Cohort Study.

Optimal Treatment Duration in Metastatic Renal Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors: Should We Treat Beyond Two Years? - Beyond the Abstract

Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR Cohort.

Delayed pancreatic metastasis from renal cell carcinoma managed with pazopanib and stereotactic ablative body radiotherapy.

Histopathology and outcomes of non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus: systematic review and meta-analysis.

Clinical outcomes and prognostic factors in patients undergoing radical nephrectomy with lymphadenectomy for pN1 renal cell carcinoma.

ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway.

Prostate Cancer

Barriers and Facilitators of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer.

MUlticentre REtrospective Comparison of Definitive EBRT with or Without HDR BRAchytherapy Boost in Patients with Locally-Advanced Prostate Cancer and Regional Lymph NOde Metastases (MUREBRANO) - a Propensity Score Matched Analysis - Beyond the Abstract

A Prospective Provincial Registry of 18F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men - Beyond the Abstract

Predictors of Toxicities and Oncological Outcomes Following Postoperative Ablative Radiotherapy (POPART) for Biochemical Recurrence - Beyond the Abstract

Implementation of a biparametric prostate MRI protocol with a recall system for intravenous contrast: an analysis of recall rates and comparison of PI-RADS category distribution.

Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy.

Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy.

Prognostic Implications of Very High Decipher Scores in Prostate Cancer: Towards a Refined Genomic Risk Classification.

An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer.

Use of staging in intermediate-risk prostate cancer: A real-world data analysis.

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Rectal Swab-based Targeted Prophylactic Antibiotics Reduce Infectious Complications After Transrectal Prostate Biopsy: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Urinary Organs-at-Risk for Radiotherapy Following Radical Prostatectomy: Contouring Guidelines on Behalf of the Francophone Group of Urological Radiation Therapy (GFRU) - Beyond the Abstract

Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005.

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer.

Immunotherapy in Metastatic Prostate Cancer: Current Realities and Future Horizons - Beyond the Abstract

A Sensitive and Specific Non-Invasive Urine Biomarker Panel for Prostate Cancer Detection - Beyond the Abstract

Inflammatory Bowel Disease vs. Adverse In-Hospital Outcomes after Radical Prostatectomy - Beyond the Abstract

The Emerging Role of PARP Inhibitors in Prostate Cancer: A Narrative Review - Beyond the Abstract

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Racial and ethnic differences in valuation of life expectancy in prostate cancer treatment decision making.

Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer.

Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer.

SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients.

A Report on the Use of Biparametric MRI in Prostate Cancer Diagnosis: A Two-Year Single Centre Experience.

Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study).

How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated.

Diagnostic Utility of 18F-DCFPyL PSMA PET/CT-Ultrasound Fusion Biopsies Across the Prostate Cancer Spectrum.

Interventions for patients with prostate cancer on active surveillance: a narrative review.

Upper Tract Tumors

Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI score.

Accuracy and limitations of ureteroscopic biopsy in the staging and grading of upper tract urothelial carcinoma: A retrospective analysis at a large tertiary center.

Deficient DNA mismatch repair and Nectin-4 expression in upper tract urothelial carcinoma (UTUC).

Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.

Robot-Assisted Radical Nephroureterectomy for Locally Advanced Upper Tract Urothelial Carcinoma: A Multicenter Study by the Junior ERUS/YAU Working Group on Robot-Assisted Surgery - Beyond the Abstract

Testicular Cancer

Fungating testicular germ cell tumours: Case report and narrative review of clinical presentation and management strategies.

Evaluation of knowledge, attitudes, and behaviors of family physicians about testicular cancer and testicular self-examination: An observational study.

Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC